Cardiovascular Protection A large clinical trial of 17,000+ adults with cardiovascular disease (but no diabetes) found that semaglutide reduced heart attacks, strokes, and cardiovascular death by 20%and those benefits began showing up before appreciable weight loss occurred
In contrast, this study applied stricter inclusion criteria, restricting the analysis to large randomised cardiovascular outcome trials with a minimum sample size of 3000 participants and a minimum follow-up of at least 12 months
Eli Lilly has seen its shares surge in the last five years, with its diabetes drug Zepbound demonstrating strong results for weight loss
Only a small fraction of people who qualify for GLP-1 medications receive them
Standard-dose GLP-1 therapy has demonstrated reductions in visceral fat in clinical trials
9.3 Dependence Physical Dependence VYVANSE may produce physical dependence